Kamada (KMDA) Assets Average (2018 - 2026)
Kamada's (KMDA) quarterly Assets Average came in at $383.1 million in Q2 2026, up 3.08% on a YoY basis from $371.6 million in Q2 2025, and up 0.58% quarter-over-quarter from $380.9 million in Q1 2026.
Analysis
Kamada (KMDA) Assets Average (2018 - 2026) Analysis & Trends
Kamada (KMDA) has reported Assets Average for 9 consecutive years, with $383.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets Average rose 3.08% year-over-year to $383.1 million; the trailing twelve-month figure through Jun 2026 stood at $383.1 million (up 3.08% YoY), and the FY2025 full-year result was $375.5 million, up 3.27% from the prior year.
- Assets Average rose to $383.1 million in Q2 2026 per KMDA's latest filing, from $380.9 million in the prior quarter.
- Across five years, Assets Average topped out at $383.1 million in Q2 2026 and bottomed at $303.6 million in Q2 2022.
- Historically, Assets Average has averaged $345.7 million across 5 years, with a median of $348.1 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Assets Average jumped 47.62% in 2022, then climbed 1.92% in 2026.
- Over 5 years, Assets Average stood at $321.0 million in 2022, then gained by 7.78% to $346.0 million in 2023, then rose by 4.55% to $361.7 million in 2024, then rose by 4.49% to $378.0 million in 2025, then gained by 1.36% to $383.1 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $383.1 million, $380.9 million, and $378.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 383.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 383.09 Mn |
| Mar 31, 2026 | 380.87 Mn |
| Dec 31, 2025 | 377.96 Mn |
| Sep 30, 2025 | 372.69 Mn |
| Jun 30, 2025 | 371.64 Mn |
| Mar 31, 2025 | 373.68 Mn |
| Dec 31, 2024 | 361.73 Mn |
| Sep 30, 2024 | 351.12 Mn |
| Jun 30, 2024 | 347.11 Mn |
| Mar 31, 2024 | 349.04 Mn |
| Dec 31, 2023 | 345.98 Mn |
| Sep 30, 2023 | 325.72 Mn |
| Jun 30, 2023 | 315.59 Mn |
| Mar 31, 2023 | 319.59 Mn |
| Dec 31, 2022 | 321.01 Mn |
| Sep 30, 2022 | 311.89 Mn |
| Jun 30, 2022 | 303.62 Mn |
| Mar 31, 2022 | 310.88 Mn |
| Dec 31, 2021 | 267.60 Mn |
| Sep 30, 2021 | 216.44 Mn |